Emergence and prevention of resistance against small molecule inhibitors

Seminars in Cancer Biology

Volumn 15, Issue 6, 2005, Pages 506-514

  Wodarz, Dominik ^a   Komarova, Natalia L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; CML; Computational biology; Drug resistance; Gleevec; Imatinib; Mathematical models; Small molecule inhibitors; Somatic evolution

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL METABOLISM; CHRONIC MYELOID LEUKEMIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; HUMANS; NEOPLASMS;

EID: 24944446749     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2005.07.002     Document Type: Review

References (36)

1. T.S. Lawrence, A.W. Blackstock, and C. McGinn The mechanism of action of radiosensitization of conventional chemotherapeutic agents Semin Radiat Oncol 13 2003 13 21
2. J.A. Simon, P. Szankasi, D.K. Nguyen, C. Ludlow, H.M. Dunstan, and C.J. Roberts Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae Cancer Res 60 2000 328 333
3. B.A. Finette, A.C. Homans, and R.J. Albertini Emergence of genetic instability in children treated for leukaemia Science 288 2000 514 517
4. V. Guillemard, and H.U. Saragovi Novel approaches for targeted cancer therapy Curr Cancer Drug Targets 4 2004 313 326
5. K.W. Yee, and A. Keating Advances in targeted therapy for chronic myeloid leukaemia Expert Rev Anticancer Ther 3 2003 295 310
6. B.J. Druker Imatinib as a paradigm of targeted therapies Adv Cancer Res 91 2004 1 30
7. J.V. Melo, T.P. Hughes, and J.F. Apperley Chronic myeloid leukemia Hematology Am Soc Hematol Educ Program 2003 132 152
8. J.M. Goldman, and J.V. Melo Chronic myeloid leukemia - advances in biology and new approaches to treatment N Engl J Med 349 2003 1451 1464
9. M.V. Blagosklonny STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon' Leukemia 16 2002 570 572
10. K.M. Shannon Resistance in the land of molecular cancer therapeutics Cancer Cell 2 2002 99 102
11. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci USA 2005;102:9714-9.
12. F.M. Schabel Jr., H.E. Skipper, M.W. Trader, W.R. Laster Jr., D.P. Griswold Jr., and T.H. Corbett Establishment of cross-resistance profiles for new agents Cancer Treat Rep 67 1983 905 922
13. F.M. Schabel Jr., M.W. Trader, W.R. Laster Jr., T.H. Corbett, and D.P. Griswold Jr. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice Cancer Treat Rep 63 1979 1459 1473
14. A.J. Coldman, and J.H. Goldie A stochastic model for the origin and treatment of tumors containing drug-resistant cells Bull Math Biol 48 1986 279 292
15. S. Bonhoeffer, R.M. May, G.M. Shaw, and M.A. Nowak Virus dynamics and drug therapy Proc Natl Acad Sci USA 94 1997 6971 6976
16. R.M. Ribeiro, and S. Bonhoeffer Production of resistant HIV mutants during antiretroviral therapy [see comments] Proc Natl Acad Sci USA 97 2000 7681 7686
17. R.M. Ribeiro, S. Bonhoeffer, and M.A. Nowak The frequency of resistant mutant virus before antiviral therapy Aids 12 1998 461 465
18. McKinnell RG, Parchment RE, Perantoni AO, Pierce, GB. The biological basis of cancer. Cambridge: Cambridge University Press.
19. B. Calabretta, and D. Perrotti The biology of CML blast crisis Blood 103 2004 4010 4022
20. F. McCormick New-age drug meets resistance Nature 412 2001 281 282
21. C.B. Gambacorti-Passerini, R.H. Gunby, R. Piazza, A. Galietta, R. Rostagno, and L. Scapozza Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias Lancet Oncol 4 2003 75 85
22. V. Nardi, M. Azam, and G.Q. Daley Mechanisms and implications of imatinib resistance mutations in BCR-ABL Curr Opin Hematol 11 2004 35 43
23. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P.N. Rao Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
24. L.A. Loeb Cancer cells exhibit a mutator phenotype Adv Cancer Res 72 1998 25 56
25. T.D. Tlsty, B.H. Margolin, and K. Lum Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis Proc Natl Acad Sci USA 86 1989 9441 9445
26. L.A. Loeb, C.F. Springgate, and N. Battula Errors in DNA replication as a basis of malignant changes Cancer Res 34 1974 2311 2321
27. A.J. Tipping, F.X. Mahon, V. Lagarde, J.M. Goldman, and J.V. Melo Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 98 2001 3864 3867
28. M.O. Nowicki, R. Falinski, M. Koptyra, A. Slupianek, T. Stoklosa, and E. Gloc BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks Blood 104 2004 3746 3753
29. C. Yoshida, and J.V. Melo Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease Int J Hematol 79 2004 420 433
30. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
31. N. von Bubnoff, D.R. Veach, H. van der Kuip, W.E. Aulitzky, J. Sanger, and P. Seipel A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor Blood 105 2005 1652 1659
32. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat Rev Drug Discov 3 2004 1001 1010
33. M.R. Burgess, B.J. Skaggs, N.P. Shah, F.Y. Lee, and C.L. Sawyers Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance Proc Natl Acad Sci USA 102 2005 3395 3400
34. S. Faderl, M. Talpaz, Z. Estrov, and H.M. Kantarjian Chronic myelogenous leukemia: biology and therapy Ann Intern Med 131 1999 207 219
35. M.E. O'Dwyer, M.J. Mauro, and B.J. Druker Recent advancements in the treatment of chronic myelogenous leukaemia Annu Rev Med 53 2002 369 381
36. M. Al-Hajj, and M.F. Clarke Self-renewal and solid tumor stem cells Oncogene 23 2004 7274 7282